Last reviewed · How we verify
Sequential
At a glance
| Generic name | Sequential |
|---|---|
| Also known as | Gemzar, Navelbine, Sequential Therapy for H. pylori, Esomeprazole, levofloxacine |
| Sponsor | National Cancer Center, Korea |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects (NA)
- Safety Study of Intravenous Hydrogen-Oxygen Ultrafine Bubbles in Adults (PHASE1)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers
- Effect of an Audio Instructional Program Regarding Puberty on Self-Concept and Healthy Behaviors of Teenage Girls With Visual Impairment (NA)
- Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke (NA)
- Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda (PHASE2)
- Predictive Validity and Clinical Utility of an Ultrasound-based Quantitative Risk Score for Pressure Injury in Critically Ill Patients: A Two-Phase Sequential Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequential CI brief — competitive landscape report
- Sequential updates RSS · CI watch RSS
- National Cancer Center, Korea portfolio CI